anetumab ravtansine
mAbexperimentalADC
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts. — Wikipedia
Clinical trial activity
14 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Sep 7, 2011 (NCT01439152)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Ovarian Epithelial · Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Hamartoma · Phase 2
- Lung Neoplasms · Phase 2
- Medical Oncology · Phase 1
- Mesothelin · Phase 1/Phase 2
- Mesothelioma · Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
Mechanism of action
- MesothelinBINDING AGENT
MSLN binding agent
- TubulinINHIBITOR
Tubulin inhibitor
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
- MesothelinImmunity, passive
MSLN immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- maytansinoid
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaImmunoGen ↗
- ChEMBLCHEMBL2109629 ↗
Also known as
- anetumab ravtansine
- anetumab ravtansine
- bay 94-9343
- bay 94-9343
- bay-94-9343
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03816358 | Phase 1 | Jul 1, 2019 | National Cancer Institute (NCI), University of Toronto |
| NCT03926143 | Phase 2 | Jun 3, 2019 | Bayer |
| NCT03455556 | Phase 1/Phase 2 (Phase 2) | Aug 10, 2018 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT03587311 | Phase 2 | Jun 29, 2018 | National Cancer Institute (NCI), University of Toronto |
| NCT03126630 | Phase 1/Phase 2 (Phase 2) | Feb 9, 2018 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT03023722 | Phase 2 | May 11, 2017 | Bayer, Yale University |
| NCT02824042 | Phase 1 | Sep 7, 2016 | Bayer |
| NCT02839681 | Phase 2 | Jul 7, 2016 | National Cancer Institute (NCI) |
| NCT02751918 | Phase 1 | Jun 8, 2016 | Bayer |
| NCT02696642 | Phase 1 | Apr 14, 2016 | Bayer |
| NCT02639091 | Phase 1 | Feb 3, 2016 | Bayer |
| NCT02610140 | Phase 2 | Dec 3, 2015 | Bayer, Immunogen |
| NCT02485119 | Phase 1 | Aug 14, 2015 | Bayer |
| NCT01439152 | Phase 1 | Sep 7, 2011 | Bayer |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 9 | 8 | 2 | 2011 |
| National Cancer Institute (NCI) | Government | 5 | 4 | 2 | 2016 |
| Mayo Clinic | Academic/Hospital | 2 | 1 | 1 | 2018 |
| University of Toronto | Academic/Hospital | 2 | 0 | 2 | 2018 |
| Immunogen | For profit | 1 | 0 | 1 | 2015 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2017 |
6 organizations
Page 1 / 1